Videx EC - Didanosine

Didanosine EC (Videx EC) - Didanosine EC should be administered on an empty stomach and should be swallowed intact. 

Didanosine EC (Videx EC) - Didanosine EC has not been studied in pediatric patients. Please consult the complete prescribing information for didanosine buffered formulation and pediatric powder for oral solution for dosage and administration of didanosine to pediatric patients. 

Videx EC (Didanosine). Bristol-Myers Squibb Pharmaceuticals Ltd UK Summary of product characteristics, December 2006. 

Didanosine EC (Videx EC) In combination with other antiretroviral agents for treatment of HIV-1 infection in adults whose management requires once-daily administration of didanosine or an alternative didanosine formulation. There are limited data to date to support the long-term durability of response with a once-daily regimen of didanosine. 

Didanosine EC (Videx EC) - For patients 60 kg or more, administer 125 mg once daily. Didanosine EC is not suitable for use in patients less than 60 kg with Ccr less than 10 mL/min. It is not necessary to administer a supplemental dose of didanosine EC following hemodialysis. 

Children-The pharmacokinetics of didanosine administered as Videx EC has not been studied in pediatric patients. 

Buffering agents that are compounded with didanosine to counteract its degradation by gastric acid may interfere with the absorption of other drugs that require acidity (e.g., indinavir, delavirdine, ketoconazole, fluoroquinolones, tetracyclines, dapsone). An enteric-coated formulation Videx EC) that dissolves in the basic pH of the small intestine is not susceptible to these interactions. Ganciclovir and valganciclovir can increase blood levels of didanosine. The use of zalcitabine with didanosine is not recommended because that combination carries an additive risk of peripheral neuropathy. The combination of didanosine with stavudine increases the risk of pancreatitis, hepatotoxicity, and peripheral neuropa-... 

Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002 46(2) 385-91. 

Didanosine/Videx EC (ddl) 125, 200, 250, or 400 mg enteric-coated capsules Body weight >60 kg 400 mg once daily <60kg 250mg once daily Peripheral neuropathy, pancreatitis, lactic acidosis with hepatic steatosis 0.11... 

NRTIs are faulty version reverse transcriptase. Reproduction of HIV is stalled when HIV uses NRTI instead of the normal reverse transcriptase. Dmgs within this category include Abacavir (Ziagen, ABC), Abacavir, Lamivudine (Epzicom), Abacavir, Lamivudine, Zidovudine (Trizivir), Didanosine (Videx, ddl, Videx EC), Emtricitabine (Emtriva, FTC, Coviracil), Emtricitabine, Tenofovir DF (Truvada), Lamivudine (Epivir, 3TC), Lamivudine, Zidovudine (Combivir), Stavudine (Zerit, d4T), Tenofovir DF (Viread, TDF), Zalcitabine (Hivid, ddC), and Zidovudine (Retrovir, AZT, AZV). 

---